News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
692,644 Results
Type
Article (41219)
Company Profile (401)
Press Release (651024)
Section
Business (207855)
Career Advice (1987)
Deals (35919)
Drug Delivery (84)
Drug Development (83005)
Employer Resources (168)
FDA (16210)
Job Trends (15013)
News (350860)
Policy (32944)
Tag
Academia (2617)
Africa (728)
Alliances (50438)
Alzheimer's disease (1174)
Approvals (16152)
Arizona (177)
Artificial intelligence (68)
Asia (38082)
Australia (6308)
Bankruptcy (359)
Best Places to Work (11400)
Biosimilars (61)
Biotechnology (298)
C2C Services and Suppliers (79632)
California (1585)
Canada (835)
Cancer (333)
Career advice (1656)
Cell therapy (107)
China (110)
Clinical research (64614)
Collaboration (115)
Colorado (65)
Connecticut (62)
COVID-19 (2529)
Cystic fibrosis (75)
Data (126)
Diabetes (66)
Diagnostics (5997)
Drug pricing (67)
Earnings (84820)
Employer resources (141)
Europe (82805)
Events (110693)
Executive appointments (90)
FDA (16375)
Florida (209)
Funding (97)
Gene therapy (84)
GLP-1 (528)
Government (4366)
Healthcare (18892)
Hotbed/Location (488272)
Idaho (56)
Illinois (240)
Indiana (135)
Infectious disease (2553)
Inflammatory bowel disease (92)
Interviews (305)
IPO (16437)
Job creations (3688)
Job search strategy (1422)
Kansas (95)
Layoffs (413)
Legal (7902)
Lung cancer (73)
Manufacturing (72)
Maryland (347)
Massachusetts (1369)
Medical device (13158)
Medtech (13161)
Mergers & acquisitions (19276)
Metabolic disorders (227)
Michigan (114)
Minnesota (207)
Neuroscience (1289)
New Jersey (481)
New York (487)
NextGen Class of 2024 (6702)
Non-profit (4519)
North Carolina (606)
Northern California (701)
Obesity (140)
Ohio (97)
Opinion (184)
Patents (56)
Pennsylvania (516)
People (57031)
Pharmaceutical (78)
Phase I (20197)
Phase II (28519)
Phase III (21143)
Pipeline (91)
Postmarket research (2582)
Preclinical (8675)
Press Release (67)
Rare diseases (120)
Real estate (5984)
Recruiting (64)
Regulatory (21550)
Research institute (2394)
Resumes & cover letters (347)
South America (1098)
Southern California (636)
Startups (3739)
Texas (188)
United States (7569)
Vaccines (459)
Washington State (242)
Weight loss (126)
Date
Last 7 days (472)
Last 30 days (2214)
Last 365 days (38518)
2024 (25212)
2023 (41014)
2022 (52276)
2021 (56766)
2020 (54924)
2019 (47420)
2018 (35698)
2017 (33026)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
692,644 Results for "revance therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Crown Laboratories to Buy Botox Rival Revance Therapeutics for $924M
The acquisition announced Monday will give Crown access to Revance’s Daxxify, a competitor to AbbVie’s Botox, which is indicated for frown lines and for cervical dystonia.
August 13, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
Revance to Participate in Upcoming June 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
May 28, 2024
·
1 min read
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced the commercial launch of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia, providing patients and physicians with a compelling new treatment option for a painful and disabling chronic condition.
May 9, 2024
·
11 min read
BioMidwest
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 14, 2024
Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units to 31 employees.
June 14, 2024
·
5 min read
Business
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
Revance Therapeutics, Inc. (NASDAQ: RVNC), today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 9, 2024
·
18 min read
Business
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market.
May 2, 2024
·
1 min read
BioMidwest
Revance to Participate in Upcoming March 2024 Investor Conferences
Revance Therapeutics, Inc. announced that the company will be participating in the following investor conferences.
February 21, 2024
·
1 min read
Deals
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock.
March 4, 2024
·
4 min read
BioMidwest
Revance Announces Proposed Public Offering of Common Stock - March 04, 2024
Revance Therapeutics, Inc. announced a proposed underwritten public offering of $100 million of its common stock.
March 4, 2024
·
5 min read
BioMidwest
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 27, 2024
Revance Therapeutics, Inc. announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units to 29 employees.
March 27, 2024
·
1 min read
1 of 69,265
Next
